Akero Therapeutics (AKRO) Proxy Filing summary

Executive summary

• A special meeting will be held for shareholders to vote on a merger with Novo Nordisk A/S, where each share will be converted into $54.00 in cash and one contingent value right (CVR) for a potential $6.00 future payment, subject to FDA approval of a key drug candidate by June 30, 2031.

• The board unanimously recommends voting in favor of the merger, the advisory compensation proposal for executives, and the adjournment proposal if more time is needed to solicit votes.

• If approved, the company will become a wholly owned subsidiary of Novo Nordisk, and its stock will be delisted from Nasdaq.

• The merger consideration represents a 42% premium over the pre-announcement share price and a 19% premium over the 30-day average.

• If the merger is not completed, the company will remain independent, but may owe a $165 million termination fee or receive a $185 million reverse termination fee under certain conditions.

Voting matters and shareholder proposals

• Shareholders will vote on: (1) adoption of the merger agreement, (2) approval of executive compensation related to the merger (advisory), and (3) adjournment of the meeting if more votes are needed.

• Approval of the merger requires a majority of outstanding shares; the compensation and adjournment proposals require a majority of shares present or represented by proxy.

• Failure to vote or instruct a broker will have the same effect as a vote against the merger proposal.

Board of directors and corporate governance

• The board formed a transaction committee to oversee the process, engaged in negotiations with multiple parties, and ultimately selected Novo Nordisk's offer as the best available.

• All current directors will resign at the effective time of the merger, and the surviving corporation's board will be appointed by Novo Nordisk.